Merck wins Hi-Tech case
Executive Summary
The Federal Circuit U.S. Court of Appeals on March 30 rejected Hi-Tech's novel argument that Merck's anti-glaucoma drug patent was not entitled to patent term extension because the patent had a terminal disclaimer. Such a disclaimer specifies that a drug is not "patentably distinct" from an earlier patent; Hi-Tech argued that the patent covering Trusopt (dorzolamide) and Cosopt (dorzolamide/timolol) would thus expire on the date of the previous patent (1"The Pink Sheet" Feb. 5, 2007, p. 8)...
You may also be interested in...
Patent Extension Arguments In Merck v. Hi-Tech Case Have Broad Implications
Generic manufacturer Hi-Tech Pharmacal is pursuing a unusual challenge to Merck's patent for the anti-glaucoma drug dorzolamide
Digital Health Roundup: Cardio Smart Watches, Pear Therapeutics Own 'Reset,' Agetech Boom
In this month’s Digital Health roundup, Medtech Insight’s Reed Miller talks about iRhythm and Withings’ smartwatches business, Barnaby Pickering reviews digital therapeutics Pear Therapeutics’ restructuring, and Marion Webb presents highlights from her new series on Agetech.
Minute Insight: Abbott Teams Up With WeightWatchers In Diabetes Management
The companies will link Abbott’s blood glucose monitoring devices to WeightWatchers’ smartphone apps and weight loss program.